Pharma BD Deal Intelligence
Roche's $4.3 billion all-cash acquisition of Spark Therapeutics landed the first FDA-approved gene therapy, Luxturna, plus a hemophilia gene therapy pipeline in SPK-8011 and SPK-9001. The bet on gene therapy platform economics has yet to translate into the hemophilia franchise Roche paid for.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Roche acquired Spark Therapeutics for $4.3B for gene therapy including Luxturna.
Feb 2023: Roche took ~CHF 740M impairment on Spark assets (Luxturna + hemophilia A/B + Pompe), part of ~$3B in 2022 gene-therapy/oncology write-downs, citing…
April 3, 2025: Roche-owned Spark Therapeutics laying off 337 of ~650 employees (more than half its workforce) in three waves (May, July, December 2025);…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Roche acquired Spark Therapeutics for approximately $4.3 billion ($114.50 per share) in an all-cash tender offer, gaining Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for a genetic disease, along with a hemophilia gene therapy pipeline.
500 US cases/yr · $15.0B Global Hemophilia Market (2024, all types)
Hemophilia A (factor VIII deficiency, ~1 in 5,000 male births) and hemophilia B (factor IX deficiency, ~1 in 20,000 male births) are X-linked recessive bleeding disorders characterized by prolonged bleeding, spontaneous hemarthroses, and risk of life-threatening hemorrhage. Standard of care has evolved from factor replacement (plasma-derived and recombinant) to extended half-life factors, the bispecific antibody emicizumab (Hemlibra) for hemophilia A, and AAV-based gene therapies for hemophilia A and B.
Hemophilia gene therapies face challenges: Roctavian (BioMarin) commercial struggles, Hemgenix (CSL Behring) for hem B at $3.5M/dose, Spark programs discontinued. Meanwhile, Hemlibra (bispecific antibody) dominates hemophilia A prophylaxis without gene therapy's complexity. The gene therapy promise of 'one and done' has been complicated by durability concerns.
400 US cases/yr · $12.0B Global Hemophilia Market (2024)
Hemophilia A affects ~20,000 Americans, caused by Factor VIII deficiency. Gene therapy aims to provide durable factor production from a single treatment. Spark's SPK-8011 was a key asset in the Roche acquisition but was ultimately discontinued due to inconsistent results.
Roctavian (BioMarin) was first approved hemophilia A gene therapy but faces commercial challenges. Hemlibra (Roche) has become the dominant prophylaxis treatment ($4B+). Factor VIII products (Advate, Eloctate) declining. The hemophilia gene therapy field has faced durability and manufacturing hurdles.
100 US cases/yr · $85M Luxturna Revenue (2023)
RPE65-associated retinal dystrophy is an ultra-rare inherited condition causing progressive vision loss. Luxturna (voretigene neparvovec) was the first FDA-approved gene therapy for a genetic disease (2017), delivering a functional RPE65 gene via AAV2. The small patient population limits commercial potential.
Luxturna's $850K per-patient price and ultra-rare population (~100 new eligible patients/year) limit commercial scale. Revenue peaked at ~$85M. Roche has faced challenges with gene therapy manufacturing and durability questions. The product remains commercially viable but not a blockbuster.
100 US cases/yr · $85M Luxturna Revenue (2023)
Biallelic RPE65 mutation-associated retinal dystrophy is an autosomal recessive form of Leber Congenital Amaurosis (LCA2) / early-onset severe retinal dystrophy. LCA affects ~2-3 per 100,000 newborns and is a leading cause of childhood blindness. Hallmarks include severe visual impairment from infancy, nystagmus, photophobia, and progressive retinal degeneration. RPE65 mutations disrupt the visual cycle, impairing 11-cis-retinal regeneration in retinal pigment epithelium.
Spark/Roche (Luxturna / voretigene neparvovec-rzyl): first FDA-approved AAV2-based in vivo gene replacement therapy for biallelic RPE65-associated retinal dystrophy (2017). Competitive landscape remains limited: MeiraGTx/Janssen's AAV5-RPE65 program (botaretigene sparoparvovec / AAV-RPE65) is in late-stage development as a potential next-generation gene therapy. ProQR's sepofarsen (RNA antisense, CEP290-LCA10) targets a different LCA subtype. No approved small-molecule alternative exists.
Roche completed $4.3B acquisition of Spark Therapeutics, gaining Luxturna gene therapy and hemophilia A/B gene therapy pipeline after extended antitrust review.
Roche recorded full $2.4B goodwill impairment after shelving hemophilia A gene therapy SPK-8011. Luxturna revenue declined 59% YoY to ~$20.5M.
Roche overhauled Spark gene therapy unit, shelving SPK-8011 (hemA) and recording $2.4B in goodwill impairment. Luxturna sales declined 59% to ~$20M in 2024.
Roche completed full integration of Spark, ending it as a separate entity. Remaining gene therapy programs refocused on select indications.
Near-total write-down. Hemophilia gene therapies failed, Luxturna cratered, $2.4B impairment charges. A cautionary tale for gene therapy M&A.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Spark Therapeutics Inc. (this deal) | 2019 | $4.3B | 27 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Gene Therapy deals